1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Predictive factors for exacerbation and re-exacerbation in chronic obstructive pulmonary disease: an extension of the Cox model to analyze data from the Swiss COPD cohort

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          The Swiss COPD cohort was established in 2006 to collect data in a primary care setting. The objective of this study was to evaluate possible predictive factors for exacerbation and re-exacerbation.

          Methods

          In order to predict exacerbation until the next visit based on the knowledge of exacerbation since the last visit, a multistate model described by Therneau and Grambsch was performed.

          Results

          Data of 1,247 patients (60.4% males, 46.6% current smokers) were analyzed, 268 (21.5%) did not fulfill spirometric diagnostic criteria for COPD. Data of 748 patients (63% males, 44.1% current smokers) were available for model analysis. In order to predict exacerbation an extended Cox Model was performed. Mean FEV 1/FVC-ratio was 53.1% (±11.5), with a majority of patients in COPD GOLD classes 2 or 3. Hospitalization for any reason (HR1.7; P = 0.04) and pronounced dyspnea (HR for mMRC grade four 3.0; P < 0.001) at most recent visit as well as prescription of short-acting bronchodilators (HR1.7; P < 0.001), inhaled (HR1.2; P = 0.005) or systemic corticosteroids (HR1.8; P = 0.015) were significantly associated with exacerbation when having had no exacerbation at most recent visit. Higher FEV 1/FVC (HR0.9; P = 0.008) and higher FEV 1 values (HR0.9; P = 0.001) were protective. When already having had an exacerbation at the most recent visit, pronounced dyspnea (HR for mMRC grade 4 1.9; P = 0.026) and cerebrovascular insult (HR2.1; P = 0.003) were significantly associated with re-exacerbation. Physical activity (HR0.6; P = 0.031) and treatment with long-acting anticholinergics (HR0.7; P = 0.044) seemed to play a significant protective role. In a best subset model for exacerbation, higher FEV 1 significantly reduced and occurrence of sputum increased the probability of exacerbation. In the same model for re-exacerbation, coronary heart disease increased and hospitalization at most recent visit seemed to reduce the risk for re-exacerbation.

          Conclusion

          Our data confirmed well-established risk factors for exacerbations whilst analyzing their predictive association with exacerbation and re-exacerbation. This study confirmed the importance of spirometry in primary care, not only for diagnosis but also as a risk evaluation for possible future exacerbations.

          Trial registration

          Our study got approval by local ethical committee in 2006 (EK Nr. 170/06) and was registered retrospectively on ClinicalTrials.gov ( NCT02065921, 19 th of February 2014).

          Related collections

          Most cited references22

          • Record: found
          • Abstract: found
          • Article: not found

          Susceptibility to exacerbation in chronic obstructive pulmonary disease.

          Although we know that exacerbations are key events in chronic obstructive pulmonary disease (COPD), our understanding of their frequency, determinants, and effects is incomplete. In a large observational cohort, we tested the hypothesis that there is a frequent-exacerbation phenotype of COPD that is independent of disease severity. We analyzed the frequency and associations of exacerbation in 2138 patients enrolled in the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study. Exacerbations were defined as events that led a care provider to prescribe antibiotics or corticosteroids (or both) or that led to hospitalization (severe exacerbations). Exacerbation frequency was observed over a period of 3 years. Exacerbations became more frequent (and more severe) as the severity of COPD increased; exacerbation rates in the first year of follow-up were 0.85 per person for patients with stage 2 COPD (with stage defined in accordance with Global Initiative for Chronic Obstructive Lung Disease [GOLD] stages), 1.34 for patients with stage 3, and 2.00 for patients with stage 4. Overall, 22% of patients with stage 2 disease, 33% with stage 3, and 47% with stage 4 had frequent exacerbations (two or more in the first year of follow-up). The single best predictor of exacerbations, across all GOLD stages, was a history of exacerbations. The frequent-exacerbation phenotype appeared to be relatively stable over a period of 3 years and could be predicted on the basis of the patient's recall of previous treated events. In addition to its association with more severe disease and prior exacerbations, the phenotype was independently associated with a history of gastroesophageal reflux or heartburn, poorer quality of life, and elevated white-cell count. Although exacerbations become more frequent and more severe as COPD progresses, the rate at which they occur appears to reflect an independent susceptibility phenotype. This has implications for the targeting of exacerbation-prevention strategies across the spectrum of disease severity. (Funded by GlaxoSmithKline; ClinicalTrials.gov number, NCT00292552.)
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Clinical Significance of Symptoms in Smokers with Preserved Pulmonary Function.

            Currently, the diagnosis of chronic obstructive pulmonary disease (COPD) requires a ratio of forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC) of less than 0.70 as assessed by spirometry after bronchodilator use. However, many smokers who do not meet this definition have respiratory symptoms.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The economic burden of COPD.

              COPD is one of the leading causes of morbidity and mortality worldwide and imparts a substantial economic burden on individuals and society. Despite the intense interest in COPD among clinicians and researchers, there is a paucity of data on health-care utilization, costs, and social burden in this population. The total economic costs of COPD morbidity and mortality in the United States were estimated at $23.9 billion in 1993. Direct treatments for COPD-related illness accounted for $14.7 billion, and the remaining $9.2 billion were indirect morbidity and premature mortality estimated as lost future earnings. Similar data from another US study suggest that 10% of persons with COPD account for > 70% of all medical care costs. International studies of trends in COPD-related hospitalization indicate that although the average length of stay has decreased since 1972, admissions per 1,000 persons per year for COPD have increased in all age groups > 45 years of age. These trends reflect population aging, smoking patterns, institutional factors, and treatment practices.
                Bookmark

                Author and article information

                Contributors
                pascal.urwyler@unibas.ch
                Nebal.AbuHussein@usb.ch
                pierre-olivier.bridevaux@hopitalvs.ch
                pchhajed@gmail.com
                Thomas.Geiser@insel.ch
                Peter.Grendelmeier@ksbl.ch
                ladina.jooszellweger@claraspital.ch
                malcolm.kohler@usz.ch
                Sabrina.Maier@ksbl.ch
                david.miedinger@unibas.ch
                michael.tamm@usb.ch
                robert.thurnheer@stgag.ch
                Thomas.Dieterle@ksbl.ch
                +41 61 925 21 80 , joerg.leuppi@ksbl.ch
                Journal
                Multidiscip Respir Med
                Multidiscip Respir Med
                Multidisciplinary Respiratory Medicine
                BioMed Central (London )
                1828-695X
                2049-6958
                5 February 2019
                5 February 2019
                2019
                : 14
                : 7
                Affiliations
                [1 ]ISNI 0000 0004 1937 0642, GRID grid.6612.3, University Clinic of Medicine, Cantonal Hospital Baselland, , University of Basel, ; Rheinstrasse 26, 4410 Liestal, Switzerland
                [2 ]ISNI 0000 0004 1937 0642, GRID grid.6612.3, University Hospital Basel, , University of Basel, ; Spitalstrasse 21, 4031 Basel, Switzerland
                [3 ]ISNI 0000 0001 2322 4988, GRID grid.8591.5, Hospital of Valais, , University of Geneva, ; Avenue du Grand-Champsec 80, 1950 Sion, Switzerland
                [4 ]ISNI 0000 0001 0726 5157, GRID grid.5734.5, University Hospital Bern (Inselspital), , University of Bern, ; Freiburgstrasse 18, 3010 Bern, Switzerland
                [5 ]ISNI 0000 0004 1937 0642, GRID grid.6612.3, St. Clara Hospital, , University of Basel, ; Kleinriehenstrasse 30, 4002 Basel, Switzerland
                [6 ]ISNI 0000 0004 1937 0650, GRID grid.7400.3, University Hospital Zurich, , University of Zurich, ; Rämistrasse 100, 8091 Zürich, Switzerland
                [7 ]Cantonal Hospital of Muensterlingen, Spitalcampus 1, 8596 Münsterlingen, Switzerland
                Article
                168
                10.1186/s40248-019-0168-5
                6364405
                0fbcf32a-f4b7-4a0d-8261-06909d5133df
                © The Author(s). 2019

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 17 September 2018
                : 27 November 2018
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/100004336, Novartis;
                Award ID: NA
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/100008349, Boehringer Ingelheim;
                Award ID: NA
                Award Recipient :
                Categories
                Original Research Article
                Custom metadata
                © The Author(s) 2019

                Respiratory medicine
                copd,exacerbation,re-exacerbation,primary health care,risk factors
                Respiratory medicine
                copd, exacerbation, re-exacerbation, primary health care, risk factors

                Comments

                Comment on this article